OverviewSuggest Edit

Harpoon Therapeutics is an immuno-oncology company which uses a proprietary technology platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases. The Company has designed a novel antibody-based drug discovery platform called TriTAC™ that unleashes the target cell killing properties of a patient’s own immune system through T cell activation.

TriTAC™ antibodies are designed to simultaneously bind to cancer cells and T cells, causing the attached T cells to release toxic factors leading to destruction of the attached target cell. In addition, TriTAC™ antibodies are engineered to bind to human serum albumin which allows for less frequent dosing, and their relatively small size allows for improved penetration into tumor tissue.

TypePublic
Founded2015
HQSouth San Francisco, CA, US
Websiteharpoontx.com
Employee Ratings4.8

Latest Updates

Employees (est.) (Feb 2019)45
Job Openings17
Revenue (FY, 2020)$17.4 M(+202%)
Share Price (Sept 2021)$9
Cybersecurity ratingAMore

Key People/Management at Harpoon Therapeutics

Gerald McMahon

Gerald McMahon

President and CEO, Director
Natalie R. Sacks

Natalie R. Sacks

Chief Medical Officer
Susan Dana Jones

Susan Dana Jones

Senior Vice President, Product Development
Rick Austin

Rick Austin

Vice President, Research
Holger Wesche

Holger Wesche

Chief Scientific Officer
Georgia L. Erbez

Georgia L. Erbez

Chief Financial Officer
Show more

Harpoon Therapeutics Office Locations

Harpoon Therapeutics has offices in South San Francisco and Louisville
South San Francisco, CA, US (HQ)
4000 Shoreline Ct #250
Louisville, KY, US
462 S 4th St
South San Francisco, CA, US
131 Oyster Point Blvd #300
Show all (3)

Harpoon Therapeutics Financials and Metrics

Harpoon Therapeutics Revenue

Harpoon Therapeutics's revenue was reported to be $17.44 m in FY, 2020
USD

Revenue (FY, 2020)

17.4m

Net income (FY, 2020)

(49.9m)

EBIT (FY, 2020)

(51.3m)

Market capitalization (9-Sept-2021)

293.0m

Closing stock price (9-Sept-2021)

9.0

Cash (31-Dec-2020)

21.2m

EV

285.4m
Harpoon Therapeutics's current market capitalization is $293 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

708.0k4.8m5.8m17.4m

General and administrative expense

3.4m3.6m6.1m22.4m16.2m

R&D expense

7.8m13.6m26.4m41.6m52.6m

Operating expense total

11.1m17.2m32.5m64.0m68.8m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.1m1.1m1.4m3.3m2.8m3.9m

General and administrative expense

5.8m3.7m8.5m3.9m3.9m4.4m

R&D expense

9.4m10.0m9.5m12.5m11.9m13.1m

Operating expense total

15.2m13.7m18.0m16.4m15.9m17.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

985.0k29.4m89.5m88.7m21.2m

Prepaid Expenses

559.0k224.0k730.0k2.5m3.7m

Current Assets

8.3m29.6m90.2m150.6m129.8m

PP&E

90.0k2.1m3.0m11.4m10.2m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

27.9m95.9m52.1m56.8m36.2m34.7m22.7m

Prepaid Expenses

1.1m2.1m3.4m1.8m5.6m3.2m2.9m

Current Assets

28.9m140.7m137.3m123.0m128.7m174.8m157.7m

PP&E

2.3m5.5m11.8m11.8m11.0m10.8m10.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(11.4m)(16.8m)(27.4m)(55.6m)(49.9m)

Depreciation and Amortization

198.0k366.0k644.0k900.0k2.1m

Accounts Payable

570.0k804.0k2.6m(1.8m)(1.2m)

Cash From Operating Activities

(10.8m)1.7m(27.1m)(2.9m)(8.6m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(11.9m)(17.6m)(13.6m)(25.4m)(41.3m)(12.6m)(25.2m)(38.6m)

Depreciation and Amortization

244.0k447.0k297.0k596.0k400.0k503.0k1.0m1.5m

Accounts Payable

(12.0k)(10.0k)(771.0k)(876.0k)(697.0k)(1.1m)(1.0m)(815.0k)

Cash From Operating Activities

(10.9m)(20.7m)(12.4m)(25.4m)(36.6m)(17.5m)20.0m6.6m
USDFY, 2016

Financial Leverage

1.9 x
Show all financial metrics

Harpoon Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Harpoon Therapeutics Online and Social Media Presence

Embed Graph

Harpoon Therapeutics News and Updates

Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provided a pipeline update on its four clinical stage programs, including updating the interim data pr…

Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today presented interim data from the ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in pa…

Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting

Management to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT on June 4, 2021 Management to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT on June 4, 2021

Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021

SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the availability of three poster presentations at the American Association for Cancer Resea…

Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is an exper…

Harpoon Therapeutics to Participate in 33rd Annual Roth Conference

SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a pan…
Show more

Harpoon Therapeutics Blogs

Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon , Ph.D., President and Chief Executive Officer, will participate in

Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Presented updated interim Phase 1/2a clinical trial data for PSMA-targeting TriTAC ®   HPN424 in prostate cancer at ASCO Annual Meeting Provided clinical trial updates for three additional TriTAC programs and ProTriTAC platform SOUTH SAN FRANCISCO, Calif. , Aug.

Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Presented encouraging data   at the AACR Annual Meeting on potential therapeutic effects of TriTACs   and   ProTriTACs Appointed experienced biotech leader A lan Colowick, M.D., to board of directors Clinical data updates for a ll four   TriTAC clinical programs expected   in 2021 SOUTH SAN

Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit

SOUTH SAN FRANCISCO, Calif. , April 28, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon , Ph.D., President and Chief Executive Officer, will participate in a

Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021

SOUTH SAN FRANCISCO, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Provided positive update on its four TriTAC ® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer Nominated first ProTriTAC™ candidate, HPN601 and presented promising preclinical data Clinical data updates for all
Show more

Harpoon Therapeutics Frequently Asked Questions

  • When was Harpoon Therapeutics founded?

    Harpoon Therapeutics was founded in 2015.

  • Who are Harpoon Therapeutics key executives?

    Harpoon Therapeutics's key executives are Gerald McMahon, Natalie R. Sacks and Susan Dana Jones.

  • How many employees does Harpoon Therapeutics have?

    Harpoon Therapeutics has 45 employees.

  • What is Harpoon Therapeutics revenue?

    Latest Harpoon Therapeutics annual revenue is $17.4 m.

  • What is Harpoon Therapeutics revenue per employee?

    Latest Harpoon Therapeutics revenue per employee is $387.6 k.

  • Who are Harpoon Therapeutics competitors?

    Competitors of Harpoon Therapeutics include Olema Oncology, APEIRON Biologics and Coherus BioSciences.

  • Where is Harpoon Therapeutics headquarters?

    Harpoon Therapeutics headquarters is located at 4000 Shoreline Ct #250, South San Francisco.

  • Where are Harpoon Therapeutics offices?

    Harpoon Therapeutics has offices in South San Francisco and Louisville.

  • How many offices does Harpoon Therapeutics have?

    Harpoon Therapeutics has 3 offices.